Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390624 · ClinicalTrials.gov registry record · Phase 2
Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol
A Phase 2 study of Mortality and Acute Renal Failure, sponsored by Rocky Mountain Cancer Centers.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00390624 is a Phase 2 study of Mortality and Acute Renal Failure that has completed, run by Rocky Mountain Cancer Centers. The registered enrollment target is 20 participants, below the 96,354-participant average among 6 other Mortality trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00390624, a Phase 2 study of Mortality and Acute Renal Failure, has completed, sponsored by Rocky Mountain Cancer Centers.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to combine Urodilatin (ANP analogue), which will increase glomerular filtration rate (GFR), and mannitol, which will increase the rate of urinary flow and solute excretion. We intend to treat twenty consecutive allogeneic bone marrow transplant patients in a phase II study comparing results with historical controls. We hypothesize that the incidence of renal dysfunction, ARF and thus mortality in allogeneic bone marrow transplantation can be significantly reduced by the use of protective agents Urodilatin and mannitol. We feel that this combination is best administered prior to and during the first two weeks of treatment when patients encounter immunosuppressive agents and the onset of early transplantation complications.
Conditions Studied
Interventions
- DRUG URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)
- DRUG MANNITOL
Study Locations (1)
Colorado
- Rocky Mountain Cancer Centers 1800 Williams Street, Suite 200 - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390624
The ClinicalTrials.gov registry entry for NCT00390624 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96,354-participant average among 6 other Mortality trials with a reported enrollment target (100% lower). The listed sponsor is Rocky Mountain Cancer Centers, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Mortality appearing as the primary indexed condition, and to 2 interventions - of which URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE) is the first listed.
NCT00390624 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT00390624 about?
NCT00390624 is a clinical study titled "Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol". The purpose of the study is to combine Urodilatin (ANP analogue), which will increase glomerular filtration rate (GFR), and mannitol, which will increase the rate of urinary flow and solute excretion. We intend to treat twenty consecutive allogeneic bone marrow transplant patients in a phase II stud...
What is the current status of trial NCT00390624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-07. Estimated completion is 2006-12.
What conditions does trial NCT00390624 study?
This clinical trial studies the following conditions: Mortality, Acute Renal Failure, Renal Dysfunction.
What interventions are being tested in trial NCT00390624?
The interventions under investigation include: URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE) (DRUG), MANNITOL (DRUG).
Who is sponsoring clinical trial NCT00390624?
This trial is sponsored by Rocky Mountain Cancer Centers, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390624 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mortality
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minocycline in Stroke Study at Maimonides
RECRUITING · Phase 2
-
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
RECRUITING · Phase 3
-
NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data
ACTIVE NOT RECRUITING
-
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness
COMPLETED · NA
-
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
COMPLETED · NA
-
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.